Extracellular matrix components and inflammatory pathways via secreted IL-10 and MMP9 from autologous engineered macrophages

This therapeutic approach utilizes autologous macrophages engineered to overexpress Interleukin-10 (IL-10) and Matrix Metalloproteinase-9 (MMP9) to treat chronic inflammatory and fibrotic diseases, such as liver cirrhosis (Resolution Therapeutics, 2024). IL-10 serves as a potent anti-inflammatory cytokine that suppresses pro-inflammatory signaling and promotes a restorative macrophage phenotype (UniProt P22301). MMP9 is an enzyme capable of degrading components of the extracellular matrix, specifically collagen type IV and gelatin, which are primary constituents of fibrotic scar tissue (UniProt P14780). By delivering these factors locally via engineered cells, the strategy aims to simultaneously resolve inflammation and remodel the pathological matrix (Moroni et al., 2019). This dual action facilitates tissue regeneration and restores organ function. Clinical development in this area, such as RTX-001, focuses on providing a cell-based alternative to organ transplantation for end-stage liver disease (Resolution Therapeutics, 2024).

Other names

Engineered macrophage therapyIL-10/MMP9 macrophage therapyRTX-001 mechanismMacrophage-based ECM remodeling

Engineered macrophages are delivered to the site of injury where they secrete MMP9 to degrade excessive extracellular matrix (fibrosis) and IL-10 to polarize the local environment toward an anti-inflammatory state.